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Autism spectrum disorder (ASD) is a syndrome that affects normal brain development
and is characterized by impaired social interaction as well as verbal and non-verbal
communication and by repetitive, stereotypic behavior. ASD is a complex disorder arising
from a combination of multiple genetic and environmental factors that are independent
from racial, ethnic and socioeconomical status. The high heritability of ASD suggests a
strong genetic basis for the disorder. Furthermore, a mounting body of evidence implies
a role of various ion channel gene defects (channelopathies) in the pathogenesis of
autism. Indeed, recent genome-wide association, and whole exome- and whole-genome
resequencing studies linked polymorphisms and rare variants in calcium, sodium and
potassium channels and their subunits with susceptibility to ASD, much as they do with
bipolar disorder, schizophrenia and other neuropsychiatric disorders. Moreover, animal
models with these genetic variations recapitulate endophenotypes considered to be
correlates of autistic behavior seen in patients. An ion ﬂux across the membrane regulates
a variety of cell functions, from generation of action potentials to gene expression and
cell morphology, thus it is not surprising that channelopathies have profound effects on
brain functions. In the present work, we summarize existing evidence for the role of ion
channel gene defects in the pathogenesis of autism with a focus on calcium signaling and
its downstream effects.
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AUTISM AND AUTISM SPECTRUM DISORDERS
Autism is a disease that dramatically affects brain function early in
development. Its societal consequence and costs are enormous,
currently costing over $130 billion per year in the USA alone
(Mandell and Knapp, 2012). Worse, its prevalence has been
increasing over the last decade with current Center for Dis-
ease Control estimates suggesting that nearly 2% of children are
affected (Blumberg et al., 2013).
Symptoms of autism typically start between the second and
third year of life and cause problems of a wide range of severity in
various areas of development. It is a neurodevelopmental disorder
with three core behavioral features: (1) qualitative impairment in
social skills, (2) delayed or disordered language and communica-
tion skills, and (3) restricted and repetitive behaviors. The autistic
spectrum disorders (ASD), the preferred term for this broad con-
stellation of pervasive developmental disorders, all share the same
three characteristic core deﬁcits. The clinical diagnosis of autism
is made by specially trained physicians and psychologists who
perform evaluations focused on detailed histories and behavioral
observations. ASD diagnosis for research studies is stricter, more
time consuming and quantitative, but even at this most reﬁned
levelASDremains a groupof developmental disorders that are only
behaviorally, not yet pathophysiologically, deﬁned (Filipek, 2005).
With the May 2013 publication of the new American Psychiatric
AssociationDiagnostic and StatisticalManual (DSM-5), all autism
subtypes will be merged into one umbrella diagnosis of ASD.
Objective quantiﬁable biochemical markers of this disease have
been very hard to come by. However, the high heritability (h2)
of ASD, which while still controversial has been calculated at
up to 90%, makes it one of the most highly heritable behav-
ioral disorders (Hallmayer et al., 2011; Devlin and Scherer, 2012).
This provides powerful assurance that genes and the biochemi-
cal pathways they subserve underlie the phenotype. Identifying
such alterations in affected individuals would provide an added
dimension to the phenotype, perhaps reﬁning more coherent sub-
groups of ASD (endophenotypes). Environmental impacts, also
clearly implicated by monozygotic twins who are discordant for
ASD (Hallmayer et al., 2011), may be best understood to perturb
these same pathways. Those genes additionally lead to personal-
ized medicine, potentially serving as new molecular diagnostics of
the disease and as targets for the development of new classes of
highly selective medications, much as has been the case for cancer.
Evidence suggests a complex multigenic etiology of many, if not
most cases of ASD. Emergent evidence from the genetic architec-
ture is beginning to implicate aberrant neuronal signaling in ASD,
and several cases strongly implicate a channelopathy pathogenesis
of the disorder.
DEFECTIVE CHANNEL FUNCTION IN AUTISM
Ion channels are a large family of transmembrane proteins that
provide ions a passive pathway throughwhich they can rapidly dif-
fuse down their electrochemical gradient across the hydrophobic
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barrier of the membrane (Hille, 2001). The standing electrochem-
ical gradients that drive passive ion movements though channels
are established by energy dependent active transport mechanisms
such as ion pumps and ion carriers (Gargus, 2008). Ion channels
conduct ions four orders of magnitude faster than pumps and
carriers, so in many ways channels act like highly selective water
ﬁlled pores that can be opened and closed in a controlled fashion
(gated) to allow a speciﬁc ion species to ﬂow. This causes a minis-
cule chemical ﬂux but an appreciable electrical current sufﬁcient
to change the membrane potential toward the Nernst potential
of the conducted ion. Since the sodium-potassium ATPase ion
pump maintains a cytoplasm high in K+ and low in Na+, oppo-
site to the cell exterior, the Nernst potential is interior negative
for K+ and interior positive for Na+ as it is for Ca2+. The chan-
nel’s predominant permeant ion species is dictated by the nature
of the channel’s selectivity ﬁlter. At rest the predominating mem-
brane permeability is for K+. This means that an interior positive
depolarization is created by opening Na+ and Ca2+ channels, an
increasingly negative hyperpolarization created by opening K+
channels, and, since the Cl− Nernst potential usually is near the
resting potential, a stabilization of the membrane potential is
created by opening Cl− channels.
Ion channel families vary in their mechanism of gating
(Figure 1). One large family of channels gate by sensing changes
in the electrical potential across the membrane – the voltage-gated
ion channels. These channels respond to a membrane potential
change by undergoing a conformational change from “closed” to
“open.” In the “open” conducting state the channel’s own ionic
current ﬂows and thereby further alters the membrane poten-
tial. This behavior is critical to their function in perpetuating
a propagating action potential (AP). As a patch of membrane
begins to depolarize, voltage-gated Na+ and Ca2+ channels begin
to open, increasing the membrane permeability to sodium and
calcium, driving the membrane potential further toward their
inside-positiveNernst potential, and hence explosively driving still
more adjacent voltage-gated channels to open. Ultimately these
channels intrinsically “inactivate” to cease conducting. Finally,
voltage-gated K+ channels open to repolarize the membrane,
converting the dormant “inactive” sodium and calcium chan-
nels into a “closed” (but openable) state again, in preparation for
conducting another AP.
A second large class of channels play a role in initiating an
AP by inducing the triggering depolarization – the ligand-gated
ion channels. They gate in response to the channel protein,
typically located at the synaptic junction between cells, bind-
ing a ligand released into the synapse. The binding of a wide
range of extracellular and intracellular diffusable ligands is able
to directly gate ion channels, and many of these ligands are
classical synaptic neurotransmitters such as acetylcholine or
dopamine. In addition, a large family of ion channels is indi-
rectly gated by ligands, many by the same neurotransmitters
mentioned above, but in this case neurotransmitter binding
occurs to a heptahelical G-protein coupled receptor (GPCR)
and the channel is activated by a second messenger ligand,
such as cyclic AMP, or a covalent modiﬁcation, such as protein
phosphorylation.
Like sodium, calcium passively enters the cytoplasm across the
plasma membrane and is cleared from the cytoplasm to a level
far below extracellular levels by a host of ion pumps and carri-
ers at the expense of metabolic energy. For most ion channels
FIGURE 1 | Ion channel families and their mechanism of gating.
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it is predominantly the electrical consequences of channel acti-
vation that underlie their physiology and pathophysiology, but
calcium is an important exception to this rule, since it plays
an additional critical role in coupling electrical activity to bio-
chemical pathways. Similar to sodium, calcium is eliminated
back out across the plasma membrane, but it is also uniquely
sequestered for subsequent rapid release within intracellular cal-
cium storage sites (Brini and Carafoli, 2011). Cytosolic calcium
signals thus originate by either the rapid release of the intracel-
lular stores through intracellular ion channels or by extracellular
calcium entering through ion channels across the plasma mem-
brane. The intracellular calcium release channels have complex
gating that includes responsiveness to plasmamembrane ion chan-
nel protein voltage-sensitive conformational changes, changes in
levels of cytosolic signaling intermediates, such as inositol 1,4,5-
triphosphate (IP3) and changes in cytosolic calcium levels. Until
recently the endoplasmic reticulum (ER) had been thought to
contain the only dynamic intracellular pool of ionized calcium
to participate in cellular signaling. This intracellular store could
be rapidly released via intrinsic ER channels, the inositol 1,4,5-
triphosphate receptors (IP3R) and the ryanodine receptors (RyR).
Once released, this calcium would activate a host of kinases, ion
channels and transcription factors, and then be resequestered via
the ER’s calcium ATPase pump (SERCA). While mitochondria
have long been known to sequester the vast majority of intra-
cellular calcium, only relatively recently has the dynamic nature
of this mitochondrial calcium pool been recognized (Spät et al.,
2008; Szabadkai and Duchen, 2008) and shown to communicate
with the ER in the generation of rapid calcium signals, forming a
bidirectional link between energy metabolism and cellular signals
transmitted via changes in the cytosolic free calcium ion concen-
tration (Danial et al., 2003; Patterson et al., 2004; Hayashi and Su,
2007).
Calcium signals are one of the most universal and ancient of
cellular signals (Berridge et al., 2000). It is a versatile biological
signal, known to regulate membrane potential, ion transporters,
kinases, transcription factors and even cellmorphology. It is there-
fore not surprising that a diverse host of diseases are coming to
be recognized to be caused by disruptions of intracellular calcium
homeostasis. This is an emerging pathophysiological mechanism
of disease, a calciumopathy (Stutzmann et al., 2006; Bezproz-
vanny and Gargus, 2008; Betzenhauser and Marks, 2010; Feske,
2010; Cain and Snutch, 2011), a special subset of the ion channel
channelopathy diseases (Gargus, 2003, 2008, 2009).
ASD IN TIMOTHY SYNDROME HAS A CALCIUM
CHANNELOPATHY PATHOGENESIS
The phenotype of Timothy syndrome (TS) involves multiple sys-
tems and speciﬁcally heart, brain, immune and skin cells. It
includes mild dysmorphology of the face and syndactyly of ﬁn-
gers and toes, suggesting a perturbation of developmental signals.
It is a simple autosomal dominant syndromic disease with high
penetrance, implying that one defective copy of a single speciﬁc
gene is sufﬁcient to produce the full spectrum of disease. Clinically
TS is predominated by prolonged ventricular repolarization and
the lethal cardiac arrhythmia syndrome long QT (LQT), so called
because of its characteristic EKG ﬁnding of a rate-corrected QT
(QTc) interval of between 480 and 700 ms (Splawski et al., 2004).
In addition to the dysmorphology, other variable extra-cardiac
symptoms include seizures, hypotonia, immune deﬁciency and
hypoglycemia. Remarkably, over 80% also have ASD (Splawski
et al., 2004, 2005, 2011). The same rare speciﬁc allele of CACNA1C,
a gene that encodes the “cardiac-expressed” voltage-gated calcium
channel, was found to cause TS in all 12 original de novo unrelated
cases (Splawski et al., 2004), suggesting that there must be only a
very limited range of changes to channel function that create the
diverse tissue phenotypes.
Long QT helped establish our understanding of channelopathy
pathogenesis and it has nowbeen shown to be caused bymutations
in all of the cardiac ion channels that contribute to the ventric-
ular AP (Bokil et al., 2010). The pathogenic alleles in these eight
ion channel loci and four loci encoding channel-interacting pro-
teins (LQT 1–12) all prolong the repolarization of the working
myocardium, prolonging the QT interval and setting the stage for
a fatal arrhythmia. Like most of the other LQT mutations, TS (also
called LQT8) is a simple monogenic dominant channelopathy, but
unlike the others is also highly penetrant for a neurodevelopmen-
tal phenotype on the autism spectrum (Splawski et al., 2004, 2005,
2011).
Since so much is understood about the pathogenesis of LQT
and the biophysics of the ion channels involved, and since TS
makes it so clear that a speciﬁc mutation in this calcium channel
causes both LQT and autism, TS holds an incomparable potential
to reveal the pathophysiology of autism. The TS mutant channel
expressed in the heart is also expressed in the neurons of the brain,
and itmust cause the symptoms in both organs since TS is a simple
monogenic disease causing both phenotypes.
Only rare missense alleles have been recognized at the
CACNA1C locus, and the speciﬁc recurrent de novo TS muta-
tion, G406R, is located in the minor alternatively spliced exon 8A
of the gene. Two other alleles in this locus cause a very similar syn-
drome, but without the syndactyly. These are found in exon 8, not
8A, suggesting cutaneous expression of only the minor transcript
(Splawski et al., 2005). The two exons are mutually exclusive, with
the vast majority of the mRNA containing exon 8, and both exons
encoding the same protein domain. The splicing is developmen-
tally regulated and ismediated by the polypyrimidine tract binding
protein PTB (Tang et al., 2011). One of the exon 8 alleles produces
exactly the same G406R missense as the classic TS mutation, but
causes a severe early lethal disease, likely because of the higher
abundance of this transcript isoform. The other allele in this exon,
G402S,was only found in amosaic individual, suggesting thatmost
mutations in this gene are not compatible with viability. Indeed,
even for the classical TS alleles somatic mosaicism seems to play a
signiﬁcant role in the variability of this syndrome (Etheridge et al.,
2011). More recently, a novel de novo TS allele was identiﬁed in
constitutively expressed exon 38, A1473G (Gillis et al., 2012). This
caused the full TS syndrome, including the minor transcript phe-
notype of syndactyly, but it was severe like other major transcript
alleles, and also caused stroke. The position of this mutation in
the channel protein is very similar to the position of the G402S
mutation, only in a different “pseudo-monomer” domain of the
pseudo-tetrameric structure of this large channel protein. It sug-
gests a special function for the end of transmembrane segment 6,
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since this novel lesion is three amino acids away from the end of
segment 6 in Domain IV whereas G402S is in the same position
in Domain I and G406R is nearby. A conserved structural motif
containing these mutated amino acids is found in all four pseudo-
monomer domains and they appear to tightly interact with one
another to form the closed state of the channel pore (Depil et al.,
2011). There are additional suggestions that this domain plays a
role in the oligomerization of these channels into synchronized
channel clusters capable of enhanced calcium signaling (Dixon
et al., 2012), potentially through interaction with anchoring pro-
teins, such as AKAP150 (Cheng et al., 2011) since a TS mutation
alters this molecular function as well. Although highly sugges-
tive clinical ﬁndings have been observed with the A1473G mutant
allele, functional studies of this novel allele have not yet been
performed (Gillis et al., 2012).
The TS channel conducts a major component of the inward
calcium current underlying the depolarized QT interval. A length-
ening of theQT to produce the LQT characteristic of the syndrome
suggests that excess current is conducted by the mutant chan-
nel. This is supported by the ﬁnding that the two missense alleles
at this locus that cause the short QT Brugada syndrome, A39V
and G490R, are loss-of-function lesions (Antzelevitch et al., 2007;
Brugada et al., 2012). It is also supported by the pharmacology of
the channel, since the channel opener Bay K 8644 can mimic the
TS arrhythmia and the channel blocker verapamil can be used to
treat TS (Jacobs et al., 2006; Sicouri et al., 2007).
Kinetic analysis of in vitro-expressed mutant and WT versions
of the TS channel reveal that the major effect of the TS mutation
is to alter the speed with which the opened conducting chan-
nel returns to a non-conducting conformation through a process
called channel inactivation (Antzelevitch et al., 2007; Barrett and
Tsien, 2008). As would be predicted from the cardiac ﬁndings in
this disorder, channel inactivation caused by changes in the mem-
brane potential (referred to as voltage-dependent inactivation,
VDI) are slowed, but there is additionally a different mechanism
of inactivation regulated directly by calcium itself, and this process
is greatly accelerated by the mutation. The net result of the mutant
is a very rapid inactivation of half the current, and then a very slow
inactivation of the remainder (Barrett and Tsien, 2008).
Induced pluripotent stem cells (iPSC) from TS patient ﬁbrob-
lasts (Yazawa et al., 2011) were produced and these reprogrammed
cells were differentiated ﬁrst into cardiomyocytes. These cells
recapitulated in vitro the prolonged APs, irregular electrical activ-
ity and abnormal calcium signals of LQT, and roscovitine, a
compound that accelerated VDI restored calcium and electrical
signaling toward control. These iPSC were also differentiated into
cortical neurons (Pas¸ca et al., 2011) and they showed wide APs
and increased calcium signals, similar to the cardiomyocytes. In
the neurons altered patterns of calcium-dependent gene expres-
sion were observed, and some of these loci had previously been
implicated inASD. In addition, abnormal levels of the neurotrans-
mitters norepinephrine and dopamine were observed. Like the
cardiomyocytes, all of these phenotypes were reversibly corrected
with roscovitine (Pas¸ca et al., 2011). However, a different neuronal
phenotype, dendrite retraction, also altered in the TS cells, was
not associated with calcium permeation, but instead with ectopic
activation of RhoA (Krey et al., 2013). Together these iPSC results
suggest that there may be cellular phenotypes of TS of potential
use in high-throughput screens for novel molecules to treat the
clinical syndrome.
Whole animal phenotypes of ASD were also recapitulated
with TS alleles. Heterozygous TS transgenic mice carrying a
poorly expressed construct with the exon 8 G406R mutation
showed abnormal behavioral phenotypes thought to model ASD.
They showed altered ultrasonic vocalizations and social behav-
ior, restricted, repetitive and perseverative behaviors, and altered
responses to fear conditioning (Bader et al., 2011).
Since LQT is a hyper-excitability syndrome, it suggests that neu-
ronal hyper-excitability is a route to ASD much as it is for seizures
and epilepsy, a condition long-recognized highly co-morbid with
ASD. As is discussed later, co-morbidity can most simply be seen
to arise from a shared genetic architecture of these diseases, with a
set of alleles and loci contributing increased susceptibility to both
disorders. Since hyper-excitability is such a multifaceted perturba-
tion of fundamental signaling mechanisms, it holds the potential
of representing a core deﬁcit in ASD, rendering it a neurobiolog-
ical, rather than strictly behavioral, disorder. The recognition of
such a core deﬁcits brightens the prospect that new molecular tar-
gets can be discovered in ASD against which new generations of
drugs can be developed for this disease.
THE IMPACT OF MUTATIONS IN OTHER CALCIUM CHANNEL
SUBUNITS IN ASD
While it is most straightforward to see the importance of calcium
channel signaling abnormalities in autism through the lens of TS,
the TS mutations clearly do not account for even a tiny fraction
of cases with typical ASD. The key difference is that TS is a highly
penetrant simple dominant disease with known causative single
gene mutation, whereas most ASD behave as a complex multi-
genic disorder (Persico and Napolioni, 2013). This means that
mutations contributing to typical ASD cannot be said to “cause
ASD” but only to incrementally enhance susceptibility to the dis-
ease – the phenotype only being observed if a sufﬁcient number
of such contributing alleles are co-inherited, likely together with
exposure to additional environmental stressors of the system. This
leads to the typical inheritance pattern of a complex multigenic
disorder that shows only a clustering of ASD in families, no simple
segregation of the trait (Splawski et al., 2006). Another signature
that shows the interaction of multiple risk alleles in developing
the phenotype of ASD is that while identical (monozygotic) twins,
who share 100% of their alleles, are reported up to 80–90% con-
cordant for the disorder, dizygotic fraternal twins – genetically
similar to sibs in sharing 50% of their alleles – are only about 30%
concordant, but are still affected at about 20 times the general
population risk (Ronald and Hoekstra, 2011). That there even is
such a thing as an“environmental stressor” in the pathophysiology
of ASD is demonstrated by the existence of discordant monozy-
gotic twins who arose from the same fertilized egg and who share
their entire genome in common yet have vastly different pheno-
types. This discordance is a hopeful sign that therapeutics could
be found to mitigate dysfunction in a susceptible genetic back-
ground. However, it will likely require a detailed understanding
of the genetic architecture of this complex disease before these
non-genetic stressors can be identiﬁed.
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The calcium channel family is well-recognized to cause chan-
nelopathy diseases. The close paralogs of the TS locus, CACNA1S
and CACNA1A have long been recognized to have highly pen-
etrant, simple dominant mutant alleles that cause, respectively,
the skeletal muscle diseases hypokalemic periodic paralysis and
malignant hyperthermia (Maclennan and Zvaritch, 2011), and
the neurological diseases hemiplegic migraine, episodic ataxia
and spinocerebellar ataxia (Gargus, 2009; Pietrobon, 2010). Fur-
thermore, simple dominant pathogenic mutations have also been
identiﬁed in many of the accessory subunits of these channels as
well.
There are, in addition, further diverse suggestions that “weak,”
poorly penetrant ASD-susceptibility alleles at other calcium chan-
nel loci are germane to typical ASD (Table 1). First, mutations in
several other calcium channel alpha subunit neuronal paralogs of
the TS/LQT8 channel have been found in subjects withASD,where
they behave more like those mutations contributing to a multi-
genic disease described above. They do not neatly segregate with
ASD in a family, but instead appear to contribute susceptibility to
autism pathogenesis (Splawski et al., 2006).
The ﬁrst example of such a paralog is the gene CACNA1H. In
the families segregating mutations in this gene several cases of
ASD are observed, all carrying the mutant allele, however, not all
with the allele manifest diagnosable ASD. The “risk allele” simply
is shown to cluster in such cases of familial autism (Splawski et al.,
2006). More recently deep resequencing of functional genomic
regions identiﬁed potentially causal rare variants contributing to
ASD inCACNA1F, anX-linked gene.This genewasﬁrst recognized
to be a locus of Stationary Night Blindness (Strom et al., 1998)
but this resequencing study observed that, in addition to the eye
ﬁndings, epilepsy and ASD occurred in individuals carrying gain-
of-function mutations, whereas loss-of-function lesions caused
only the classic Stationary Night Blindness phenotype (Myers
et al., 2011). This again suggests that ASD pathogenesis arises from
excess calcium signaling, but as was the case for the complex gat-
ing changes seen in TS, perhaps perturbed calcium homeostasis is
more broadly responsible. CACNA1G, another calcium channel
alpha subunit paralog, is mapped to the chromosome 17q11-
q21 ASD-susceptibility region. It was found to contain single
nucleotide polymorphisms (SNPs) associated with ASD in male
multiplex families in an AGRE cohort (Strom et al., 2010). The
same locuswas again found to contain twoASD-associated SNPs in
a subsequent larger study that also identiﬁedASD-associated SNPs
in CACNA1I and the TS locus CACNA1C (Lu et al., 2012). Indeed,
there is even growing evidence that CACNA1C itself also contains
other weak alleles that contribute broadly to cortical dysfunction,
such as in schizophrenia, bipolar disease (BPD) and major depres-
sion (Sklar et al., 2008; Green et al., 2010; Thimm et al., 2011). In
some cases mutations of this CACNA1C alpha subunit also alter
an adjacent calcium channel accessory subunit, as in the case of an
interstitial deletion at chromosome 12p13.33 that deleted both the
CACNA1C major subunit and the CACNA2D4 accessory calcium
channel subunit genes, causing ASD-like developmental delays in
two sibs and their father (Abdelmoity et al., 2011). In a subsequent
study of copy number variants (CNVs) in ASD, two affected sibs
were found to have a 2p:12p translocation that, again, resulted in
the deletion of both genes as well (Smith et al., 2012). Eichler and
Meier (2008) also identiﬁed exon-disrupting CNV deletions not
found in healthy controls in the paralog calcium channel accessory
subunit CACNA2D3 in their analysis of recurrent CNV hotspots
in ASD (Girirajan et al., 2013). Eichler’s group further identiﬁed
de novo rare alleles in alpha subunit lociCACNA1D andCACNA1E
as “top de novo risk mutations” for autism in a whole exome rese-
quencing study (O’Roak et al., 2012b), and, using a high density
custom microarray in a different cohort of ASD, implicated a com-
pletely different type of calcium channel, a calcium-permeable
cation channel called a transient receptor potential (TRP) chan-
nel, encoded by TRPM1. This gene had previously been shown
to carry pathogenic alleles for Complete Congenital Stationary
Night Blindness (Audo et al., 2009) and subsequently to partic-
ipate in the metabotropic glutamate receptor signaling cascade
(Devi et al., 2013). They observed that the CNV deletion at the
15q13.3 locus that is enriched in ASD, was found in 5 out of 2,588
cases, and that although CHRNA7 had been previously impli-
cated as contributing to neurological defects in this lesion (see
below), in their cohort they found no deletions of this gene, but
instead found that all ﬁve cases had deletions of TRPM1 in this
locus, including one homozygous deletion never observed in a
control.
In a very powerful genome-wide association study (GWAS)
of SNPs in a huge European cohort of over 30,000 cases and
a similar number of matched controls, speciﬁc variants under-
lying genetic effects shared between the ﬁve disorders: ASD,
attention deﬁcit-hyperactivity disorder, bipolar disorder, major
depressive disorder, and schizophrenia revealed that only 4 of the
∼25,000 human loci were associated with neuropsychiatric dis-
ease at“genome-wide signiﬁcance”– the probability of chance false
positive associationbeing less than 5 in 100million (p< 5× 10−8).
Two of these associated genes encoded calcium channel subunits,
CACNA1C, the TS locus, and the accessory calcium channel sub-
unit CACNB2 (Psychiatric Genomics Consortium et al., 2013).
Interestingly, although no strong allele of CACNB2 has yet been
found to cause a TS-like syndrome, dominant pathogenic loss-
of-function missense alleles of the locus cause the short QT
arrhythmia Brugada syndrome (Antzelevitch et al., 2007). This is
the same syndrome caused by dominant loss-of-function alleles at
CACNA1C, where a gain-of-function allele causes TS. This ﬁnd-
ing powerfully implicates the function of this multimeric calcium
channel and TS-like pathophysiology in this wide spectrum of
neuropsychopathology. It is also consistent with the observation
that genes encoding plasma membrane calcium pumps, responsi-
ble for creating the calcium gradients dissipated by the channels,
have been repeatedly associated with ASD. The calcium ATPase
geneATP2B2 encodes theplasmamembrane calcium-transporting
pump which extrudes Ca2+ from cytosol into extracellular space,
and three studies from different populations have reported asso-
ciation between this locus and ASD (Carayol et al., 2011; Prandini
et al., 2012; Yang et al., 2013). It is further intriguing to note that
paralogs of the other Brugada syndrome loci encoding sodiumand
potassium channels, also feature prominently in the architecture
of ASD, as discussed below. The typical channelopathy lesions in
well-understood monogenic diseases of heart, muscle and nerve
causemembrane hyper-excitability. Hence,mutations in Ca2+ and
Na+ channels, which physiologically excite a tissue, typically have
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gain-of-function lesions, while mutations in K+ and Cl− chan-
nels, which physiologically stabilize excitable tissue, typically have
pathological lesions that diminish their current (Gargus, 2008).
SODIUM CHANNEL DEFECTS IN ASD
As mentioned above, mutations in three voltage-gated sodium
channel subunits cause Brugada syndrome, the cardiac alpha
subunit SCN5A, and accessory subunits SCN1B and SCN3B.
Mutations in neuronal paralogs of the alpha subunit, SCN1A
and SCN2A, had long ago been observed in rare cases of famil-
ial autism (Weiss et al., 2003) and prior to that had been shown to
contribute dominant pathogenic alleles to the seizure syndrome
GEFS+. SCN1A had also been shown to carry haploinsufﬁcient
dominant null alleles in the severe seizure syndrome SMEI/Dravet
syndrome (reviewed in Ma and Gargus, 2007), as well as missense
alleles in the migraine syndrome familial hemiplegic migraine
(FHM3; Dichgans et al., 2005; Gargus and Tournay, 2007). Fur-
thermore, SCN1A alleles have also been recognized to cause autism
and epilepsy phenotypes together with biopsy-proven mitochon-
drial disease (Craig et al., 2012). It is particularly intriguing that
the autism-associated SCN1A alleles are quite different from the
seizure alleles, which produce a more severe lesion in the channel
protein, but that they are very similar to the mutations found in
the FHM3 families (Gargus and Tournay, 2007). These alleles are
found to disrupt cytosolic loop domains at the C-terminus of the
protein, a region originally identiﬁed in the Brugada SCN5A chan-
nel as an EF-hand-containing domain key to channel inactivation
(Glaaser et al., 2006) and a site of regulatory calmodulin binding
(Kim et al., 2004). Both FHM3 and autism alleles of SCN1A per-
turb calmodulin-interacting intracellular regions of the channel
protein. These regions connect this sodium channel into the cal-
cium signaling pathways of the neuron since they interact with
calmodulin that serves as an actual bound protein subunit of the
channel (Gargus, 2009).
More recently strong evidence has been building for a role
of lesions in neuronal voltage-activated sodium channel alpha
subunits in typical polygenic ASD (Table 2). Whole-exome rese-
quencing of nearly 1000 individuals uniquely identiﬁed SCN1A as
the sole gene in which two independent probands had non-sense
variants that disrupted the same gene, a highly signiﬁcant result
(Sanders et al., 2012) and this ﬁnding was again conﬁrmed in a
separate large resequencing study that found de novo protein alter-
ing mutations in the gene in probands with ASD (O’Roak et al.,
2012a). Loss of function lesions in this region had previously been
recognized by array-comparative genome hybridization (CGH)
detection in a child with autistic features carrying a de novo dele-
tion of chromosome 2q24.2-q24.3, the region containing SCN2A
and SCN3A (Chen et al., 2010).
Because of the fact that mutations in SCN1A are capable of
causing seizure syndromes and seizures are frequently comorbid
with ASD, the question arises whether seizure activity causes the
impairments observed in ASD (Catarino et al., 2011), or if the ion
channel dysfunction itself, independent of seizures, contributes
to the ASD pathophysiology. This question has been elegantly
approached in heterozygous KO mouse models of SMEI/Dravet
syndrome. Scn1a+/− heterozygous KO mice develop multiple
behavioral phenotypes, including increased anxiety, hyperactivity
and stereotyped behaviors, in addition to seizures and ataxia (Han
et al., 2012). However, using inhibitory RNA (RNAi) expression
of SCN1A could be reduced in focal regions of the brain without
producing clinical or EEG-detectable seizures (Bender et al., 2013).
In this case focal loss of expression of this channel was found to
cause spatial memory impairment, without an effect on response
to a novel object or in more general measures of exploration. This
spatial performance was signiﬁcantly related to hippocampal theta
frequency (an inducer of LTP, see below) in the control group, but
this relationship was abolished after RNAi knockdown, consis-
tent with a role of this channel in learning paradigms dependent
upon hippocampal theta oscillations and independent of a role in
seizures. This is consistent with a critical role for SCN1A in the
network oscillations contributing to cognitive function (Bender
et al., 2013).
Another sodium channel alpha subunit gene came to be impli-
cated in ASD by whole-genome resequencing in a small family
quartet having just one affected proband, an unaffected sib and
two unaffected parents. The study uncovered yet another neu-
ronal sodium channel paralog underlying the phenotype of autism
with epilepsy. They discovered a de novo heterozygous missense
mutation in SCN8A in the proband that alters an evolutionarily
conserved residue in one of themost abundant sodiumchannels in
the brain. Further, they carried out biophysical measurements of
the properties of themutant channel and demonstrated a dramatic
increase in persistent sodium current and incomplete channel
inactivation (Veeramah et al., 2012), demonstrating a gain-of-
function lesion similar to that seen in the pathogenic cardiac and
muscle sodium channel paralogs.
A different set of mechanistically unbiased approaches to ASD
allele discovery have also pointed to neuronal sodium channel
paralogs. The ﬁrst study involved a large survey of consan-
guineous Middle Eastern families with autism and the technique
of microarray homozygosity mapping. This technique will detect
rare variants that, through common decent from a shared parental
ancestor, cause recessive disease. The study identiﬁed one family
that segregated a homozygous deletion of SCN7A (Morrow et al.,
2008). This gene lies adjacent to SCN1A within the sodium chan-
nel gene cluster at the autism-5 locus (AUT5) on chromosome 2.
While its mRNA is neuronally expressed, no function has yet been
observed for the putative ion channel it encodes (Saleh et al., 2005).
It is rapidly evolving, having arisen from SCN1A by endodupli-
cation (Plummer and Meisler, 1999), and such rapidly evolving
genes are a signature of genes potentially playing human-speciﬁc
roles, intriguing candidates in neuropsychiatric diseases (Berglund
et al., 2009).
While the Brugada syndrome associated sodium channel beta
subunit locus SCN1B is well recognized to carry alleles that cause
the GEFS+ seizure phenotype (Wallace et al., 1998) and can cause
ASD together with this syndrome (Dixon-Salazar et al., 2004), no
mutations in these accessory sodium channel subunits have yet
been clearly associated with the ASD phenotype independent of
seizures.
The sum of the evidence on neuronal sodium channels suggests
that hyper-excitability-causing gain-of-function lesions that delay
inactivation of the channel predominate, much as is seen in LQT
and MHS. However, there are also clear cases of deletions causing
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haploinsufﬁciency, as in SMEI, and even absence of the channels,
as in SCN7A. These can only be interpreted as loss-of-function
lesions that, most simply, reduce membrane excitability. Again,
the fact that calmodulin acts as a modulatory subunit for the alpha
subunits in this family of channels, that the alpha loci carry the pre-
ponderance of the evidence for association with ASD and that the
calciumopathy disease mechanism is caused by pathogenic mus-
cle and cardiac sodium channel paralogs also serves to implicate
abnormal calcium homeostasis in these neuronal lesions.
POTASSIUM CHANNEL DEFECTS IN ASD
Calcium-activated potassium channels are central components
of neuronal calcium signaling and neurosecretory pathways and
critical regulators of pacemaker-like rhythmic, bursting synap-
tic activity, particularly involving aminergic transmitters such as
dopamine. As such they were early identiﬁed candidate genes
associated with neuropsychiatric phenotypes (Chandy et al., 1998;
Grube et al., 2011). The large conductance (BK) family mem-
ber KCNMA1 has more recently been implicated in ASD. Strong
pathogenic alleles at this locus cause a distinctive epilepsy syn-
drome, “Generalized epilepsy and paroxysmal dyskinesia” (Du
et al., 2005), and the locus was shown to be physically disrupted
on chromosome 10 by a balanced reciprocal translocation in a
patient with ASD. Following functional assessment via electro-
physiology demonstrated reduced activity of the channel and
conﬁrmed its functional haploinsufﬁciency. Furthermore, the
case-control component of the study revealed a missense allele
that altered a conserved domain of the channel in another subject
with ASD, with no variants detected in the control population
(Laumonnier et al., 2006). More recently this BK channel was
implicated in ASD because of its regulation by the fragile X
mental retardation 1 protein (FMRP), the loss of which pro-
duces the monogenic ASD syndrome Fragile X (FXS), discussed
further below. In presynaptic membranes FMRP was shown
to physically interact with the BK channel through its regula-
tory KCNMB4 subunit. The loss of FMRP, via a murine fmr1
KO lesion that models FXS, reduces channel activity, slowing
membrane repolarization and broadening the AP, increasing the
presynaptic calcium inﬂux and neurotransmitter release, dysregu-
lating synaptic transmission. This difference observed between
the control and the KO animals was abolished by the intra-
cellular calcium chelator BAPTA, suggesting that FMRP alters
the calcium sensitivity of the BK channel by its effects on the
channel’s regulatory subunit (Deng et al., 2013). This channel
subunit was further implicated in ASD by the fact that SNPs
in KCNMB4 were strongly associated with ASD and included
as one of three genes in a panel “predictive” of ASD (Skaﬁdas
et al., 2012). Another potassium channel, the A-type potassium
channel encoded by KCND2 (Gross et al., 2011) was also shown
to be altered by FMRP. In this case it followed the conventional
mechanism invoked for FXS pathogenesis, FMRP-sensitive synap-
tic protein translation downstream of the metabotropic mGluR5
glutamate receptors in the postsynaptic membrane, discussed fur-
ther below. The hippocampi of fmr1 KO animals were observed to
have hyper-excitability because of reduced levels of this important
repolarizing potassium channel (Gross et al., 2011). Additionally,
while much attention in FXS has focused upon mGluR5 receptors
and enhanced mGluR-dependent long term depression (LTD)
seen in fmr1 KO mice, FMRP binds over 400 putative mRNAs
(Ashley et al., 1993) and various approaches similarly iden-
tify several other potassium channel mRNAs as FMRP targets
(Lee and Jan, 2012).
Other classes of potassium channels have been implicated
in ASD by rare alleles and functional studies of heterologously
expressed pathogenic proteins. For example, the ATP-dependent
inward rectiﬁer potassium channel gene KCNJ10 (originally iden-
tiﬁed to carry pathogenic epilepsy alleles causing SESAME syn-
drome with ataxia, sensorineural hearing loss and tubulopathy;
Bockenhauer et al., 2009), was identiﬁed to carry missense muta-
tions that altered highly conserved residues in two unrelated
families with seizures and ASD (Sicca et al., 2011). The effects
of mutations in a heterologous expression system revealed an
increase in channel current suggesting a gain-of-function defect
(Sicca et al., 2011). TheM-current potassiumchannel subunit gene
KCNQ3 (paralog of the ﬁrst LQT gene and long-proven causal
of Benign Familial Infantile Seizures; Wang et al., 1998) and its
paralog encoding one of its heteromultimeric partners, KCNQ5,
have also been recently implicated in ASD. A de novo transloca-
tion truncating KCNQ3 was identiﬁed in a boy with autism, and
three patients with ASD were recognized to share the same rare
variant of KCNQ5 caused by a SNP that creates a missense muta-
tion that could be proven to be loss-of-function by patch clamp
recording of oocytes co-expressing both subunits (Gilling et al.,
2013). Potassium channels implicated in ASD are summarized in
Table 3.
CHLORIDE CHANNEL DEFECTS IN ASD
The balance between excitatory and inhibitory neurotransmission
(E/I balance) has long been recognized to play a critical role in
the development of neuronal circuits, the maturation of the brain
and to be impaired in several genetic and teratological models of
ASD (Eichler and Meier, 2008; Gibson et al., 2009; Gogolla et al.,
2009; Pizzarelli and Cherubini, 2011, 2013; Bateup et al., 2013; Lin
et al., 2013). Just as glutamate is the major excitatory neurotrans-
mitter in the CNS, gamma aminiobutyric acid (GABA), produced
from glutamate, is its major inhibitory neurotransmitter, and an
imbalance in the signaling of these two systems is implicated in
ASD (Gogolla et al., 2009). GABA’s actions are mediated through
the GABA A- and B- type receptors. The metabotropic GABA-B
receptors are GPCRs that function by increasing the potassium
conductance responsible for long-lasting inhibitory postsynaptic
potentials (Kuriyama et al., 2000). GABA-A receptors, on the other
hand, are heteropentamer channels comprised of two α-, two β-
and one γ- or δ-subunit (Wafford, 2005; Goetz et al., 2007). The
GABA-A receptors consist of at least 15 different receptor sub-
units, and mutations in GABA-A receptor subunits have been
frequently associatedwith epilepsy andother neuropsychiatric dis-
orders (Kang andBarnes,2013). They forma ligand-gated chloride
channel that plays a crucial role in inhibitory synaptic transmis-
sion. It is able to play this role since the chloride Nernst potential
is near the resting membrane potential of most cells, including
neurons, and opening this channel serves to anchor the potential,
preventing a depolarizing AP. It has more recently, however, been
observed that GABA can actually play the role of an excitatory
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depolarizing neurotransmitter early in development and it does so
because the intracellular chloride ion concentration in the target
neuron is elevated, rendering its Nernst potential a depolarizing
force, similar to the activation of a sodium channel. This ele-
vated intracellular chloride arises because of high activity of the
loop diuretic-sensitive Na-K-Cl-Cl electroneutral cotransporter
found ubiquitously expressed in plasma membranes, encoded by
SLC12A2. It drives chloride into the cell making use of energy
provided by the inward sodium gradient. This cotransporter is
the paralog of the kidney-speciﬁc apical membrane cotransporter
mutated in Bartter syndrome, encoded by SLC12A1, through
which bumetanide and furosemide achieve their diuretic effect.
Concomitantly through development, activity of the chloride
exportingK-Cl electroneutral cotransporter, encodedby SLC12A5,
and powered by the outward potassium gradient, is decreased.
This coordinate regulation of the two cotransporters is medi-
ated by opposite-acting protein phosphorylation events on each
cotransporter via activation of WNK serine-threonine protein
kinase (Ben-Ari et al., 2012). In KO mice lacking SLC12A5 pro-
tein, unlike WT, patch-clamp measurements demonstrated an
excitatory action of GABA (as well as another neurotransmitter
that activates chloride channels, glycine), implicating the altered
chloride gradient in this shift (Hübner et al., 2001). This has led
to the suggestion that perhaps the E/I balance problem in ASD
arises from GABA continuing to have an “immature” activating
effect at its GABA-A receptors because of an abnormal chloride
gradient. The conclusion might then be that bumetanide could
remedy that situation, restoring the gradient and GABA inhibition
and thereby prove therapeutic in ASD. A small double-blinded
clinical trial of 60 children showed some efﬁcacy on a number
of ASD assessment scales during a 3-month trial (Lemonnier et al.,
2012).
OTHER SODIUM-COTRANSPORTERS INVOLVED IN CALCIUM
SIGNALING IN ASD
The sodium-dependent solute transporters, introduced above, are
a large family of transmembrane carrier proteins. They are able to
function as secondary active transporters, moving solutes against
their electrochemical gradient into or out of cells, by tapping
the energy stored in the transmembrane sodium gradient. The
aminergic synapses rely upon members of this family to regu-
late synaptic transmission by clearing neurotransmitters that were
released into the cleft during synaptic transmission, andmutations
in these important proteins have been observed in ASD. Two ASD
subjects with CNV duplications of SLC1A1, encoding the sodium-
potassium dependent EAAT glutamate transporter found widely
distributed in the brain, were observed in a large survey of CNV
hotspots in ASD (Girirajan et al., 2013). A common polymor-
phism was also observed in SLC6A4 to be associated with ASD
(Table 4). It encodes the high-afﬁnity sodium-chloride depen-
dent serotonin transporter (5-HTT) localized in brain presynaptic
neuronal membranes (Li et al., 2012). This transporter is a prin-
cipal site of action of tricyclic antidepressants and serotonin
re-uptake inhibitors. A polymorphism in the promoter region
located 1 kb upstream of the transcription initiation site is com-
posed of repeat elements and the polymorphism is a 44-bp
indel with the short allele associated with lower transcriptional
efﬁciency. Association studies of autism with this polymorphism
have yielded conﬂicting results, but a recent large meta-analysis
of all studies failed to ﬁnd a signiﬁcant overall association
between either polymorphismand autism (Huang andSantangelo,
2008).
It is intriguing to note that anotherASD-associatedCNVdupli-
cation was found in a membrane protein participating at the
opposite end of the neurosecretion signaling pathway – the exo-
cytosis of vesicles ﬁlled with neurotransmitters. Duplications of
CADPS2, a gene encoding the Ca2+-dependent activator pro-
tein for secretion 2, a calcium-binding protein found in neurons
involved in the exocytosis of dense-core neurotransmitter vesicles,
was found in subjects with ASD (Girirajan et al., 2013). This gene
is located on chromosome 7q31.32 within the AUTS1 locus that
has been previously implicated in autism susceptibility. Alterna-
tive splicing with exon 3 skipping was observed in subjects with
autism with no splice variants found in healthy controls (Sadakata
et al., 2007). A mouse model with exon 3 skipping demonstrated
decreased reciprocal interactions, increased anxiety and decreased
exploratory behavior in open-ﬁeld tests, aswell asmaternal neglect
of newborns and altered ultrasound vocalization (Sadakata et al.,
2012).
Members of the solute carrier superfamily also mediate trans-
port across the mitochondrial inner membrane. Several studies in
ASD have focused attention on mitochondrial dysfunction (Gar-
gus and Imtiaz, 2008) and linkage and association studies have
further focused upon variation in SLC25A12 (Turunen et al., 2008;
Kim et al., 2011; Napolioni et al., 2011). This gene on 2q24 encodes
the brain-speciﬁc isoform of the mitochondrial calcium-regulated
aspartate/glutamate carrier. Candidate genes in this region were
scanned for autism-associated SNPs and two, located in introns of
SLC25A12, were found associated with the disease (Ramoz et al.,
2004). The same risk haplotype at these two SNPs was then con-
ﬁrmed to be linked and associated with ASD in a second cohort
(Ramoz et al., 2004). Subsequent studies conﬁrmed that autism
was associated with other SNPs within the locus, although none
appeared to alter function (Segurado et al., 2005). Subsequently a
study of post-mortem brain tissue showed signiﬁcantly increased
transport activity by the SLC25A12 transporter in subjects with
ASD. However, no mutations or polymorphisms were found asso-
ciated with the disease (Palmieri et al., 2010). Furthermore, all of
the excess enzyme activity found in brain samples from patients
with ASD was calcium-dependent and was found to be associated
with elevated cytosolic calcium levels in these subjects (Palmieri
et al., 2010). They found that controlling for the calcium levels,
transport activity was identical in isolated mitochondria from
patients and controls. They therefore concluded that the criti-
cal link to this altered mitochondrial metabolism observed in the
brains of patients with autismwas in fact caused by altered calcium
homeostasis, although it was never directly studied. Subsequent
studies have found overexpression of SLC25A12 in post-mortem
brain from subjects withASD (Lepagnol-Bestel et al., 2008). While
the fundamental abnormality of this transporter in ASD remains
to be unambiguously deﬁned, it is a tantalizing link between
cytosolic calcium homeostasis and mitochondrial energetics, an
often independent important mechanistic theme in ASD etiology
(Gargus, 2010).
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SYNAPSES AND DOWNSTREAM CALCIUM SIGNALING
DEFECTS IN ASD
The axonal AP-induced calcium signal culminates by initiating
the fusion of synaptic vesicles into the pre-synaptic membrane,
and in this fashion participates in diverse mechanisms of synaptic
modulation that produce synaptic plasticity and learning (Neher
and Sakaba, 2008). Crossing the synaptic cleft, the neurotrans-
mitter binds and activates its receptor, altering excitability of the
post-synaptic cell. It also often feeds back through pre-synaptic
receptors to modulate pre-synaptic vesicle fusion. Ultimately the
signal is terminated by re-uptake of the neurotransmitter from
the synaptic cleft. Calcium not only plays a role in neuronal
plasticity in modulating neurosecretion in neuronal networks,
but it additionally shapes the composition of the synaptic mem-
branes themselves through the role it plays in the calcium-sensitive
mammalian target of rapamycin (mTOR) signaling pathway of
upstream regulators and downstream effectors, many directly
implicated in model monogenic ASD syndromes.
GLUTAMATE RECEPTORS
Glutamate, the major excitatory neurotransmitter in the central
nervous system, activates two major classes of synaptic receptors:
ionotropic receptors, which are themselves ligand-gated cation
channels, and metabotropic receptors, that are heptahelical GPCR
coupled to a variety of signaling pathways through trimeric G
proteins. mGluR5, GRM5-encoded receptors, are coupled via Gq
to activate phospholipase C and in turn an IP3 and the calcium
signaling second messenger system. Phosphorylation and dephos-
phorylation of a key residue within the C-terminal domain of the
activated receptor cause synchronous, oscillatory changes in IP3
and Ca2+ levels (Bradley and Challiss, 2011).
The metabotropic glutamate receptor mGluR5 is one of the
many synaptic proteins altered in Fmr1 KO mice. FXS is an impor-
tant monogenic model of ASD (Iossifov et al., 2012), and mouse
models of FXS are based upon such knock-out (KO) mice. In
the absence of FMRP, it is widely recognized that performance in
learning paradigms is impaired in these mice and that this reca-
pitulates the phenotypes observed in FXS patients where defects
in learning are directly observed (De Rubeis et al., 2012). The
absence of FMRP in Fmr1 KO mice produces an up-regulation of
mGluR5 and an enhancement in the synaptic phenomenonof LTD
that relies upon enhanced mTOR-mediated rapamycin-sensitive
protein synthesis triggered by this receptor. This culminates in
reduction of synaptic AMPA glutamate receptors (see below) and
chronically decreased synaptic efﬁciency (Sharma et al., 2010).
Fragile X syndrome is a loss-of-function syndrome, over-
whelmingly caused by an extremely large expansion of the trinu-
cleotide CGG repeats (>200) in the 5′ non-coding portion of the
human locus, but is also caused by deletion of the locus or rare
missensemutations (Collins et al., 2010). Males are predominantly
affected, and this lesion typically results in the absence of FMRP, a
multi-functional mRNA binding protein (Ashley et al., 1993) and
ion channel regulatory subunit (Deng et al., 2013).
Carriers of one FMR1 allele with a “premutation,” a modestly
expanded trinucleotide repeat (55–200 repeats) at the FMR1 locus,
are at risk for expression of “Fragile X-associated tremor/ataxia
syndrome”(FXTAS), an aged-onsetmonogenic neurodegenerative
disorder associated with decreased FMRP levels (Feng et al.,
1995; Jacquemont et al., 2003; Sheridan et al., 2011; Cao et al.,
2013). iPS-derrived neurons harboring a stably active, modestly
expanded allele have reduced neurite length and high ampli-
tude, high frequency functionally abnormal calcium transients
compared to neurons harboring the normal active allele (Liu
et al., 2012). Moreover, a sustained calcium elevation was found
in the expanded-allele-expressing neurons after glutamate appli-
cation (Liu et al., 2012). Subsequently astrocytes derived from
heterozygousmicewith the FMRPpremutation also demonstrated
increased Ca2+ oscillations as well as increased sensitivity to gluta-
mate, despite having levels of mGluR5 receptors similar to control
(Cao et al., 2013). Comparable studies were not reported with
classical FXS alleles, however, these observations suggest a funda-
mental role of FMRP in synaptic calcium signaling that is sensitive
to disruption by pathogenic alleles at the locus and is potentially
consistent with the effects of FMRP observed on pre-synaptic BK
channels discussed above (Deng et al., 2013).
The postsynaptic membrane mGluR5 receptors are bound to
HOMER1 scaffold proteins, together with plasma membrane
GRM1-encoded mGluR1 receptors, ER-associated IP3 and RyR,
encoded by ITPR1, RYR1 and RYR2, and plasma membrane volt-
age dependent calcium channels, to form a functional signaling
complex. Together with SHANK1 and SHANK3 scaffolds it plays
a key role in facilitating intracellular calcium release and trans-
membrane calcium currents (Kato et al., 2012). Interestingly, in
Fmr1 KO mice disrupted Homer1 complex formation is observed
(Ronesi et al., 2012). There are two isoforms of Homer1, long
and short, that have opposite actions in signaling. The long form
has a coiled-coil domain through which they multimerize to act
as a scaffold. The N-terminal domain of the long form binds to
the intracellular C-terminal tail of the mGluR5 receptor and has
an ability to link them together with the IP3 receptors and other
scaffolded signaling membrane proteins and kinases (Ronesi et al.,
2012). Homer1 has several splice variants, and extracellular stim-
uli promote 3′-end processing of Homer1 pre-mRNA, leading to
the switch of poly(A) site selection. The short form of Homer1, an
immediate early gene transcript, lacks this coiled-coil domain, and
thus cannot multimerize or act as a scaffold. It therefore serves to
physically dissociate the receptor from the IP3 receptor and other
scaffolded proteins. This renders the mGluR5 receptor constitu-
tively active and agonist-independent, enhancing its signaling. In
Fmr1 KO mice mGluR5 is preferentially associated with the short
form of Homer1. This leads to an increased signaling frequency
and prolonged spontaneous persistent activity. Genetic deletion
of short-form Homer1 corrects several phenotypes in Fmr1 KO
mice, while a short mimic peptide containing the proline-rich
motif of mGluR5 that binds to Homer and disrupts the mGluR5-
Homer scaffold, in wild type mice produces several phenotypes of
Fmr1 KO mice. Together it suggests an important role of mGluR5-
long Homer signaling complexes in normal brain function and
of the short form complexes in the disease pathophysiology. In
fact, pharmacological inhibition of mGluR5 activity was proven
beneﬁcial in correction of autistic phenotypes in both animal
models and human patients, probably because of its effect on the
constitutively active mGluR5 (Michalon et al., 2012; Ronesi et al.,
2012).
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Calcium signaling through metabotropic mGluR5 receptors
additionally plays a key role in modulating the function and sub-
unit composition of ionotropic glutamate receptors at the synapse.
N-methyl-D-aspartate (NMDA) inotropic glutamate receptors are
a heterotetramer of subunits encoded byGRIN1 andGRIN2A,B,C
or D. The switch of subunits in the NMDA receptor from GRIN2B
to GRIN2A is an important example of synaptic modulation and
experience-dependent regulation of receptor subunit composition
in vivo. This long-lasting alteration of the synapse is driven acutely
by activity of mGluR5 and involves its downstream phospholipase
C, calcium release from IP3-dependent stores, and protein kinase
C activity. In mGluR5 KO mice the developmental switch is deﬁ-
cient and therefore the GRIN2B to GRIN2A switch evoked in vivo
by visual experience is absent and such learning fails (Matta et al.,
2011). The subunit switch causes important changes to NMDA
receptor function, altering the amount of calcium inﬂux through
the ionotropic receptor channel pore and the types of proteins
interacting with the intracellular domain of the receptor. These
features regulate the type of long-term synaptic plasticity (LTP or
LTD, see below) that NMDA receptor activation can induce (Liu
et al., 2004; Bartlett et al., 2007).
Long-term potentiation (LTP), the opposite of LTD, can be
induced by rapid theta burst stimulation (TBS) in hippocam-
pal slices and it relies upon two classes of iontropic glutamate
receptors, the NMDA receptors and the alpha-amino-3-hydroxy-
5-methyl-4-isoxazole propionate (AMPA) receptors, a heterote-
tramer with subunits encoded by GRIA1–4 that function coop-
eratively as ligand-gated cation channels in the post-synaptic
membrane. The AMPA subunit encoded by GRIA2 is subject to
RNA editing (CAG->CGG; changing a single amino acid within
the second transmembrane domain from glutamine to arginine)
which renders the channel impermeable to Ca2+, a feature essen-
tial to its function as a non-selective monovalent cation channel
(Barbon andBarlati, 2011). On the other hand theNMDAreceptor
channel is highly calcium permeable. However, it has a complex
double-gated mechanism that requires both binding the activating
glutamate neurotransmitter and a strong membrane depolariza-
tion, usually driven by the AMPA receptors, to remove a luminal
Mg2+ion that blocks the receptor’s channel (Ogden and Traynelis,
2011). Only a very large synaptic glutamate release activates suf-
ﬁcient AMPA channels to remove the Mg2+ ion block to provide
an NMDA calcium conductance pathway and hence provide a
post-synaptic calcium signal. LTP depends upon this change in
postsynaptic calcium since intracellular injection of the calcium
chelator EGTA blocks the development of LTP (Lynch et al., 1983).
NMDA-mediated responses are required to induce LTP but it is
through calcium-dependentmodiﬁcationof the postsynaptic neu-
ronAMPA receptor components that LTP ismanifest (Muller et al.,
1988).
Loss of FMRP also leads to changes in the synaptic phe-
nomenon of short term potentiation (STP) whereby prior activity
of a synapse enhances the probability of synaptic vesicle release
with a subsequent stimulation a short while later. This is largely
a result of residual elevated calcium levels from the pre-synaptic
priming stimulus (Fioravante and Regehr, 2011). Like LTP, STP
is considered to be one of the elemental components of informa-
tion processing at a synapse underlying plasticity and learning as it
precedes the development of LTP. Loss of FMRP leads to enhanced
responses to high-frequency stimulation and to abnormal exces-
sive enhancement of synaptic processing of natural stimulus
trains. These changes are associated with exaggerated calcium
inﬂux in presynaptic neurons during high-frequency stimulation,
enhanced synaptic vesicle recycling, and enlarged readily releasable
and reserved vesicle pools, all serving to increase signaling across
the synapse (Deng et al., 2011).
Hence results of the loss of FMRP are changes in pre-synaptic
and post-synaptic channel function, neurosecretory dysfunction
and changes in the expression of a large set of post-synaptic neu-
ronal mRNAs, many themselves changing the composition of the
post-synaptic membrane. Therefore, while FXS is a simple mono-
genic disease it produces complex polygenic dysregulation of the
synapse (De Rubeis et al., 2012). However, the sum of the evidence
is that the complex pre- and post-synaptic membrane changes
recognized in FXS participate in core fundamental processes of
synaptic plasticity and learning, are calcium sensitive, and as such
this fundamental physiological process may be a promising target
in ASD amenable to pharmacological treatment.
THE Cys-LOOP FAMILY OF nACh AND GABA RECEPTORS
The 15q11-13 inverted duplication remains the most common
chromosomal lesion in ASD, and ASD-associated CNV duplica-
tions and deletions in this region are among the most common
as well. This region spans the imprinted Angelman/Prader-Willi
region, and both Angelman syndrome (AS) and Prader-Willi
syndrome (PWS) are themselves important single locus mod-
els of ASD (Vorstman et al., 2006; Depienne et al., 2009; Dykens
et al., 2011). This region contains a cluster of inhibitory GABA-A
receptor subunit genes as well as the surprisingly related exci-
tatory α7 nicotinic acetylcholine receptor (nAChR) encoded by
CHRNA7. Both are members of the Cys-loop ligand-gated ion
channel superfamily. The GABA receptors contribute to a chloride
channel and the α7 nACh receptor is a homo-pentameric ligand-
gated calcium-conducting cation channel. In the hippocampus,
presynaptic α7 nAChRs regulate glutamate release, whereas post-
synaptic α7 nAChRs stimulate inhibitory GABAergic interneuron
activity (Johnstone et al., 2011) and the release of GABA (Adams
et al., 2012).
Chromosomalmapping studies have revealed that several of the
GABA-A receptor subunit genes are organized as clusters and one
such cluster, which consists of theGABA-A receptor β3 (GABRB3),
α5 (GABRA5) andγ3 (GABRG3) subunit genes, is located at 15q12
(Menold et al., 2001). Two SNPs located within GABRG3 show
signiﬁcant evidence for linkage disequilibrium (LD) with ASD,
suggesting that it or a gene nearby contributes to genetic risk
in ASD (Menold et al., 2001). A small sample of subjects with
ASD, studied with positron emission tomography (PET) using a
benzodiazepine receptor selective PET ligand, recently provided
preliminary direct evidence of changes in the abundance of the α5
GABA-A receptor in two regions of the brain, the amygdala and
nucleus accumbens, limbic system structures long implicated in
ASD (Mendez et al., 2013).
The molecular defects underlying AS are heterogeneous –
most commonly caused by large maternal deletions of chromo-
some 15q11-q13 – but importantly, over a dozen loss-of-function
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mutations of UBE3A cause AS, implicating it as the critical 15q
locus for this syndrome. In contrast to AS, PWS is caused by the
absence of expression of the paternally active genes in this critical
region of 15q11-13, and while it is uncertain which gene is criti-
cal, it is clear that its maternal allele is virtually inactive through
imprinting (Chamberlain and Lalande, 2010). Importantly more
than 99% of individuals with PWS have a diagnostic abnormality
in the parent-speciﬁc methylation imprint within the Prader-Willi
critical region (Cassidy et al., 2012) and there is clear evidence that
such imprinted genes in this region play a role in ASD-like phe-
notypes (Chamberlain and Lalande, 2010; Relkovic et al., 2010;
Ingason et al., 2011).
Interestingly deletion of just the small Prader-Willi imprinting
center (PWS-IC) within 15q11-13 disrupts long-range imprinted
gene expression resulting in PWS (Yasui et al., 2011), and the
two PWS-IC sites ﬂank CHRNA7. Recently, four probands were
identiﬁed with small deletions in 15q13 that included only the
CHRNA7 gene, and this was followed by the identiﬁcation of
others also with isolated heterozygous CHRNA7 gene deletions,
including the ﬁrst de novo deletion and one patient homozy-
gous for the deletion. These patients demonstrated the similar
wide range of ASD phenotypic features associated with the larger
15q11-13 microdeletions, suggesting CHRNA7 was the critical
gene responsible for the clinical ﬁndings associated with the 15q13
microdeletion syndrome (Hoppman-Chaney et al., 2013).
A physical interaction between the DNA cis PWS-IC regulatory
elements that ﬂank CHRNA7 and the protein trans regulatory
element methyl CpG binding protein 2, encoded by MeCP2, is
required for optimal expression of AS/PWS region genes impli-
cated in the ASD phenotype (Yasui et al., 2011). MECP2 acts
as a calcium-dependent transcriptional repressor for methylated
genes, a global regulator of histone function (Cohen et al., 2011;
Li et al., 2011) and plays a key role in the control of neuronal
activity-dependent gene regulation. Rett syndrome is an X-linked
dominant disorder caused by MeCP2 mutations that are lethal
in hemizygous males and cause an ASD-like syndrome in het-
erozygous females. Patients with Rett syndrome or even those
with typical ASD, revealed signiﬁcantly reduced CHRNA7 expres-
sion in the frontal cortex compared with controls, suggesting
that transcription of CHRNA7 is modulated by these regulatory
elements and is involved in ASD-like phenotypes (Yasui et al.,
2011). In heterozygous KO mice, reduced Chrna7 expression
results in decreased hippocampal α7 receptor density, abnormal
hippocampal auditory sensory processing, and increased hip-
pocampal pyramidal neuron activity, together demonstrating that
decreased receptor expression alters hippocampal inhibitory cir-
cuit function. This was associated with reduced levels of the
enzyme responsible for converting glutamate to GABA, glutamic
acid decarboxylase 1 (encoded byGad1), andwith a decrease in the
GABA-A receptors, the later only observed in themales, an intrigu-
ing ﬁnding in a target for a disease as highly sexually dimorphic as
ASD (Adams et al., 2012).
In Mecp2 KO mouse brain, the mRNA expression and pro-
tein levels of Ube3a, the target in AS, are decreased, and the
non-imprinted adjacent GABA-A receptor GABRB3 gene also
shows reduced expression (Samaco et al., 2005). Direct study of
neuronal function in the mouse Mecp2 KO Rett model revealed
that excitatory, but not inhibitory, synapses showed less sponta-
neous activity than control. This observation suggests a potential
defect in the calcium-dependent processes of excitatory neurose-
cretion and synaptic vesicle trafﬁcking (Nelson et al., 2006). Loss
of MeCP2 and doubling of MeCP2 dosage in mice have oppo-
site effects on excitatory synapse numbers in individual neurons
(Chao et al., 2007), suggesting that MeCP2 may be a rate-limiting
factor in regulating glutamatergic synapse formation, and this is
recapitulated in neurons derived from iPSCs. Neurons derived
from iPSC clones carrying 3 different MeCP2 mutations (RTT)
showed a reduction in the density of glutamatergic synapse mark-
ers when compared to WT control, and neurons derived from WT
iPSCs expressing an antisense knock-down construct of MeCP2
(shMeCP2) showed a similar reduction when compared to control
neurons expressing a scrambled control. Finally, overexpression of
MeCP2, using a lentiviral vector, increased abundance of the glu-
tamatergic marker in WT and RTT neurons, together strongly
suggesting that MeCP2 is a rate-limiting factor regulating gluta-
matergic synapse number in human neurons (Marchetto et al.,
2010).
A disturbance in neuronal calciumhomeostasis is also observed
in Mecp2 KO mice (Mironov et al., 2009), and this phenotype too
is recapitulated in iPSC-derived RTT neurons. While both WT
and RTT neurons showed similar APs and sodium and potassium
currents in response to depolarizations in this model (but not in
other RTT models; Farra et al., 2012), demonstrating that RTT
cells are not altered in maturation toward normal electrophysio-
logical activity, spontaneous calcium transients were decreased in
the RTT neurons and the frequency of calcium oscillations in RTT
neurons and in WT neurons expressing shMeCP2 was abnormally
decreased compared to controls (Marchetto et al., 2010). These
spontaneous calcium transients could be blocked with the sodium
channel blocker tetrodotoxin (TTX) or with AMPA and NMDA
glutamate receptor antagonists, and were increased by GABA-A
receptor antagonists, demonstrating the sensitivity of this cal-
cium signal to synaptic activity and the presence of glutamatergic
and GABAergic synapses in the system. Such neuronal activity-
induced calcium inﬂux can trigger the calcium/calmodulin-
dependent protein kinase (CamK), an inducer of MeCP2
phosphorylation.
The importance of GABAergic transmission in these ASD phe-
notypes is revealed by the study of KO mice lacking MeCP2
selectively only from GABA-releasing neurons. They recapitulate
numerous Rett syndrome and ASD phenotypic features, includ-
ing repetitive behaviors. Furthermore, loss of MeCP2 from just
a subset of forebrain GABAergic inhibitory neurons also reca-
pitulates many features of Rett syndrome (Chao et al., 2010).
MeCP2-deﬁcient GABAergic neurons show reduced inhibitory
quantal size, suggesting less neurotransmitter per synaptic vesi-
cle. This ﬁnding is consistent with the observed presynaptic
reduction in theGABA-synthesizing enzymes glutamic acid decar-
boxylase 1 (Gad1) and glutamic acid decarboxylase 2 (Gad2),
and decreased GABA immunoreactivity. The pattern is simi-
lar to what is observed in the Chrna7 KO mouse. Together
this suggests that MeCP2 and CHRNA7 expression is critical
for normal function of GABA-releasing inhibitory neurons and
that this may contribute to the neuropsychiatric phenotypes in
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Rett, other monogenic models of ASD, and perhaps more typical
ASD (Chao et al., 2010; Yasui et al., 2011). Together these ﬁnd-
ings link gene dysregulation in the mammalian brain within
the chromosome 15q11-q13 region with MeCP2 function, and
therefore link Rett syndrome, AS, PWS and ASD, and suggest
that ASD may be caused by the inability of neurons to generate
adaptive responses via the neuroreceptors involved in generating
synaptic calcium signals and calcium-regulated gene expression
(Qiu and Cheng, 2010).
Finally, it is intriguing that the combined modulation of
the two different “Cys-loop” superfamily receptors encoded in
the AS/PWS region, the α7 nAChR and α5 GABA-AR, alter
hippocampal function in learning paradigms. Transient appli-
cation of two separate allosteric modulators, which individually
inhibit either the inhibitory α5 GABA-ARs or enhance the
activating α7 nAChRs, only jointly causes LTP of induced
excitatory postsynaptic currents (EPSCs) in pyramidal neurons
of rat hippocampal slices (Johnstone et al., 2011). Remark-
ably this effect is replicated by a single compound that was
designed to simultaneously carry out both activities speciﬁ-
cally on these two related receptors, suggesting the therapeutic
utility of this strategy targeting the AS/PWS encoded receptors
(Johnstone et al., 2011).
mTOR SIGNALING
Mammalian target of rapamycin is a key cytosolic integrative reg-
ulator of calcium signaling and mitochondrial function created by
a large multidomain protein kinase that regulates cell growth and
metabolism in response to environmental signals (Ramanathan
and Schreiber, 2009) and several forms of synaptic plasticity
(Hoeffer and Klann, 2010; Figure 2). Upstream signals origi-
nate from plasma membrane growth factor receptors that signal
through phosphatidylinositol 3-kinase (PI3K) to Akt, or through
Ras to ERK, to the TSC1/TSC2 heteromultimer that sits at the
center of this growth factor receptor stimulated calcium signal-
ing pathway. The genes that encode these two subunits, TSC1 and
TSC2, carry dominant mutations that produce tuberous sclerosis
(TSC), another important syndromic form of ASD that impacts
synaptic calcium signaling. The protein products of these two
TSC genes heteromultimerize to negatively regulate downstream
signaling by acting as a GTPase-activating protein (GAP) for the
small GTPase RHEB, a direct activator of the protein kinase activ-
ity of mTOR. mTOR itself phosphorylates S6 kinase 1 (S6K1)
and eukaryotic translation initiation factor 4E binding protein 1
(eIF4E-BP1), leading to enhanced protein translation (Ehninger
and Silva, 2011).
Tuberous sclerosis is a neurocutaneous syndrome that produces
ASD-like behaviors, seizures, intellectual disability, tumorous
growths in the brain and characteristic skin lesions. In a TSC
mouse model created by an in vivo postnatal Tsc1 conditional KO
in only the CA-1 hippocampal neurons, hippocampal mGluR-
LTD was abolished, whereas a protein synthesis-independent form
of NMDA receptor-dependent LTD (see above) was preserved
(Bateup et al., 2011). Additionally, AMPA and NMDA receptor-
mediated EPSCs and miniature spontaneous EPSC frequency
were enhanced in Tsc1 KO neurons. These changes in synaptic
function occurred in the absence of alterations in presynaptic
FIGURE 2 | mTOR signaling.
transmitter release probability, indicating that signaling through
Tsc1/2 is required for the expressionof speciﬁc formsof hippocam-
pal synaptic plasticity and normal excitatory synaptic function
(Bateup et al., 2011).
In a different mouse model of TSC, both heterozygous and
homozygous loss of Tsc1 was limited to principal cells (PC) in
the cerebellum, a region of the brain only recently implicated in
the ASD phenotype (Tsai et al., 2012). These KO lesions decrease
PC excitability and also result in autistic-like behaviors, including
abnormal social interaction, repetitive behavior and vocalizations.
Importantly, treatment of these mutant mice with the mTOR
inhibitor rapamycin prevented the pathological and behavioral
deﬁcits, deﬁning a molecular basis for a cerebellar contribution to
ASD (Tsai et al., 2012).
The FKBP rapamycin-binding subunit of mTOR (encoded by
Fkbp1A; often called Fkbp12) is the validated target of rapamycin
and other immunosuppressant and anticancer drugs. The protein
is a cis-trans prolyl isomerase that interacts with intracellular cal-
cium release channels. Neuronal deletion of Fkbp1A is associated
with disinhibited mTOR signaling and altered synaptic plasticity,
andmemory (Hoeffer et al., 2008). TheKOmouse shows increased
basalmTORand S6K1 phosphorylation aswell as an enhancement
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in hippocampal LTP. Not unexpectedly, this enhancement was
resistant to rapamycin, but not to other blockers of protein trans-
lation. This conditional KO displayed enhanced contextual fear
memory and autistic/obsessive-compulsive-like perseveration in
several assays, together indicating that FKBP plays a critical role
in the regulation of mTOR, LTP, memory, and ASD-like behav-
iors (Hoeffer et al., 2008). Disrupting Fkbp1B with interfering
RNA (RNAi) knockdown also destabilizes Ca2+ homeostasis in
hippocampal neurons, similarly to rapamycin, and is sufﬁcient
to induce a characteristic “aged phenotype” of Ca2+ dysregula-
tion in even young rodents. This phenotype, seen in very old
animals and Alzheimer models (Gant et al., 2011), derives from
abnormal calcium signaling in hippocampal pyramidal neurons
seen as increases in several Ca2+-dependent phenomena (calcium
transients, slow after hyperpolarizations, voltage-gated calcium
channel activity, ryanodine receptor calcium release, and reduced
neuronal excitability) and causing impaired learning and memory
(Gant et al., 2011).
FAMILY OF AUTISM-RELATED DISEASES WITH DEFECTIVE
NEURONAL CALCIUM SIGNALING
A number of diseases have long been recognized to be co-morbid
with autism – seizures, migraine and BPD being the most promi-
nent (Gargus, 2009, 2010). While there are many competing
theories for such familial clustering, an important consideration
is that these superﬁcially distinct diseases share some funda-
mental components of vulnerability, likely arising from a shared
subset of susceptibility-conferring loci. Recently this was explic-
itly shown to be true for the neuropsychiatric phenotypes of
autism, ADHD, BPD, depression and schizophrenia. It was shown
that these phenotypically distinct disorders, both childhood- and
adult-onset, share common genetic alterations and hence, path-
ways (Psychiatric Genomics Consortium et al., 2013). In that
study, voltage-gated calcium signaling was shown to be a joint
common susceptibility factor for all various psychopathological
conditions.
While these complex neurological diseases are caused over-
whelmingly by heterogeneous genetic and environmental factors,
the seizure and migraine etiological neuronal phenotypes are
emerging from analysis of rare monogenic forms of these diseases.
The monogenic seizure and migraine diseases are all caused by
ion channel mutations and have a common channelopathy patho-
genesis (Dodick and Gargus, 2008). The mutations all produce
constitutionally hyper-excitable neurons that are susceptible to
“arrhythmias” or periodic decompensations, much like the LQT
heart or the MHS-periodically paralyzed muscle (Gargus, 2006,
2008, 2009). For example, the gene families (FHM1/CACNA1A,
FHM2/ATP1A2 and FHM3/SCN1A), the mutational lesions and
the integrated pathophysiology underlying FHM3, are all strik-
ingly homologous to those in epilepsy, LQT andMHS, and provide
a robust platform for understanding the pathogenesis of the cal-
cium channel autism syndrome, TS/LQT8. The FHM3 and FHM1
genes are paralogs of the sodium and calcium channel genes that
contribute to MHS (MHS2 and MHS5, respectively) and to LQT
(LQT3 and LQT8, respectively). The close relationship of the
FHM3 and autism alleles of FHM3/SCN1A has been discussed
above.
The sum of the growing evidence supports the role of calcium
signaling as one of the major participants in the pathogenesis
of ASD, making it a promising therapeutic target. Further-
more, calcium signaling abnormalities have the potential to serve
as functional biomarkers of the disease, a quantiﬁable objec-
tive measure independent of subjective behavioral assessments,
and possibly useful as a cellular diagnostic in routine clinical
care, complementing current complex neurobehavioral testing
batteries.
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